Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Statistical analysis of disease onset during lifespan with left truncation.

Biometrics·2026
Same author

Hippocampal asymmetry captures non-amyloid-related risk of memory decline and clinical progression.

The journal of prevention of Alzheimer's disease·2026
Same author

The Modifying Effect of Individual-Level Neighborhood Perceptions on the Relationship Between Census-Level Neighborhood Social Vulnerability and Cognition in Older Latinos.

International journal of environmental research and public health·2026
Same author

Eligibility of men vs. women in Alzheimer's trials: Inclusive vs. representative.

The journal of prevention of Alzheimer's disease·2026
Same author

APOE and amyloid-tau pathology in cognitively unimpaired older adults.

medRxiv : the preprint server for health sciences·2026
Same author

Study of the utility and impact of a plasma p-tau181 Alzheimer's biomarker (SUITABLE).

Alzheimer's & dementia (New York, N. Y.)·2026

Related Experiment Video

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Drug Development.

Mikaela K Nishida1, Megan G Witbracht1,2, Michelle M Nuño3

  • 1University of California, Irvine, Irvine, CA, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
PubMed
Summary

Recruitment strategies like transportation and compensation increase participation in Alzheimer's disease (AD) trials. However, these factors showed minimal differences across racial and ethnic groups, suggesting broad applicability.

More Related Videos

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Related Experiment Videos

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Area of Science:

  • Neuroscience
  • Clinical Trials
  • Alzheimer's Disease Research

Background:

  • Recruiting participants for preclinical Alzheimer's disease (AD) clinical trials presents significant challenges.
  • While strategies like reducing logistical barriers and offering incentives are studied, their differential utility across racial and ethnic groups remains underexplored.

Purpose of the Study:

  • To assess the utility of specific factors in influencing willingness to participate in preclinical AD clinical trials.
  • To examine potential differences in the utility of these factors across various racial and ethnic groups.

Main Methods:

  • A conjoint experiment was conducted involving 261 participants rating 16 hypothetical preclinical AD trial vignettes on a 7-point Likert scale.
  • Four factors were assessed: transportation provision, lifetime dementia risk assessment, cognitive test summaries, and financial compensation.
  • Generalized estimating equations were used to analyze factor utility, with separate analyses for Hispanic, non-Hispanic (NH) Asian, NH Black or African American, NH White, and NH Other participants.

Main Results:

  • Overall, transportation (0.25 utility points), dementia risk assessment (0.10 utility points), cognitive test summaries (0.30 utility points), and higher monetary compensation (0.30 utility points) significantly increased willingness to participate.
  • NH Asian participants showed less utility for transportation and higher monetary compensation compared to the full cohort.
  • NH White participants showed higher utility for dementia risk estimates and cognitive test results.

Conclusions:

  • Strategies including transportation, risk estimates, cognitive test results, and monetary compensation enhance overall willingness to join AD clinical trials.
  • These strategies demonstrated generally similar magnitudes of utility across different racial and ethnic groups, despite some specific variations observed.